Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 14 of 393 for:    PYY

Location of GLP-1 Release

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02036710
Recruitment Status : Completed
First Posted : January 15, 2014
Last Update Posted : March 28, 2014
Sponsor:
Information provided by (Responsible Party):
University of Minnesota - Clinical and Translational Science Institute

Brief Summary:

Background: Physicians do not have a unified, scientifically tested theory of causation for obesity and its comorbidities, nor do they have explanations for the mechanics of the metabolic/bariatric surgery procedures. Integral to proffered hypotheses are the actions of the hormones glucagon-like peptide (GLP-1), peptide YY (PYY), and leptin.

Study objective: To obtain blood levels of GLP-1, PYY, and leptin after stimulation of the terminal ileum and cecum by a static infusion of a food hydrolysate in morbidly obese patients undergoing a duodenal switch procedure.

Methods: Plasma levels of GLP-1, PYY, and leptin were obtained at 0, 30, 60, 90, and 120 minutes after instillation of 240 ml of a food hydrolysate into the ileum or cecum.


Condition or disease
Obesity

Layout table for study information
Study Type : Observational
Actual Enrollment : 12 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Location of Glucagon-Like Peptide (GLP)-1 Release
Study Start Date : November 2011
Actual Primary Completion Date : August 2013
Actual Study Completion Date : October 2013

Group/Cohort
Cecum
Food hydrolysate instilled into terminal cecum of patient undergoing open duodenal switch procedure. Blood samples were then obtained at baseline and at 0, 30, 60, 90, and 120 minutes for analysis of circulating GLP-1, PYY, and leptin.
Ileum
Food hydrolysate instilled into terminal ileum of patient undergoing open duodenal switch procedure. Blood samples were then obtained at baseline and at 0, 30, 60, 90, and 120 minutes for analysis of circulating GLP-1, PYY, and leptin.



Primary Outcome Measures :
  1. GLP-1 [ Time Frame: 2 hours ]
    GLP- levels were measured at intervals over two hours after static bowel food hydrolysate was infused, in patients undergoing scheduled open duodenal switch procedure.

  2. peptide YY (PYY) [ Time Frame: 2 hours ]
    PYY levels were measured at intervals over two hours after static bowel food hydrolysate was infused, in patients undergoing scheduled open duodenal switch procedure.

  3. Leptin [ Time Frame: 2 hours ]
    Leptin levels were measured at intervals over two hours after static bowel food hydrolysate was infused, in patients undergoing scheduled open duodenal switch procedure.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Study population consisted of morbidly obese individuals who had decided to undergo open duodenal switch surgery
Criteria

Inclusion Criteria:

  • Any patient who was qualified and approved for bariatric surgery and elected to undergo open duodenal switch procedure.

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02036710


Locations
Layout table for location information
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55455
Sponsors and Collaborators
University of Minnesota - Clinical and Translational Science Institute
Investigators
Layout table for investigator information
Principal Investigator: Henry Buchwald, MD, PhD University of Minnesota - Clinical and Translational Science Institute

Layout table for additonal information
Responsible Party: University of Minnesota - Clinical and Translational Science Institute
ClinicalTrials.gov Identifier: NCT02036710     History of Changes
Other Study ID Numbers: CTSI-20810
First Posted: January 15, 2014    Key Record Dates
Last Update Posted: March 28, 2014
Last Verified: March 2014

Keywords provided by University of Minnesota - Clinical and Translational Science Institute:
GLP-1
PYY
Leptin
Duodenal Switch